Elevated CEA with negative PET scan on surveillance of colorectal cancers—a role of CEA kinetics

2021 ◽  
Author(s):  
Anand Ebin Thomas ◽  
Mufaddal Kazi ◽  
Sanket Bankar ◽  
Smruti Mokal ◽  
Archi Agarwal ◽  
...  
Keyword(s):  
Pet Scan ◽  
Colorectal Cancers

PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence

2019 ◽  
Vol 20 (12) ◽  
pp. 1217-1226 ◽  
Author(s):  
Arunaksharan Narayanankutty
Keyword(s):  
Colorectal Cancer ◽  
Drug Resistance ◽  
Therapeutic Target ◽  
Clinical Evidence ◽  
Mtor Pathway ◽  
Colorectal Cancers ◽  
Patent Literature ◽  
Mtor Signalling ◽  
Natural And Synthetic

Background: Phosphoinositide 3-kinase (PI3Ks) is a member of intracellular lipid kinases and involved in the regulation of cellular proliferation, differentiation and survival. Overexpression of the PI3K/Akt/mTOR signalling has been reported in various forms of cancers, especially in colorectal cancers (CRC). Due to their significant roles in the initiation and progression events of colorectal cancer, they are recognized as a striking therapeutic target. Objective: The present review is aimed to provide a detailed outline on the role of PI3K/Akt/mTOR pathway in the initiation and progression events of colorectal cancers as well as its function in drug resistance. Further, the role of PI3K/Akt/mTOR inhibitors alone and in combination with other chemotherapeutic drugs, in alleviating colorectal cancer is also discussed. The review contains preclinical and clinical evidence as well as patent literature of the pathway inhibitors which are natural and synthetic in origin. Methods: The data were obtained from PubMed/Medline databases, Scopus and Google patent literature. Results: PI3K/Akt/mTOR signalling is an important event in colorectal carcinogenesis. In addition, it plays significant roles in acquiring drug resistance as well as metastatic initiation events of CRCs. Several small molecules of natural and synthetic origin have been found to be potent inhibitors of CRCs by effectively downregulating the pathway. Data from various clinical studies also support these pathway inhibitors and several among them are patented. Conclusion: Inhibitors of the PI3K/mTOR pathway have been successful for the treatment of primary and metastatic colorectal cancers, rendering the pathway as a promising clinical cancer therapeutic target.

scholarly journals Not All That Shines on a PET Scan Is Cancer: A Silicone-Induced Granuloma Masquerading as Malignancy

2020 ◽  
Vol 11 (1) ◽  
pp. 8-12
Author(s):  
Krishna Vedala ◽  
Philip Sobash ◽  
Deborah Johnson ◽  
Krishna Kakkera
Keyword(s):  
Pet Scan ◽  
Imaging Modalities ◽  
Ct Scans ◽  
Pet Ct ◽  
Suspicious Lesions

PET/CT scans are frequently used in the initial workup of suspicious lesions but not all that lights up on a PET is cancerous. We wish to discuss a case of silicone-induced granuloma mimicking malignancy and the role of other imaging modalities for further workup.

scholarly journals Role of FDG-PET scan in the management of pediatric mature B cell non-Hodgkin’s lymphoma. CCHE experience

2016 ◽  
Vol 28 (2) ◽  
pp. 95-99 ◽  
Author(s):  
Hany Abdel Rahman ◽  
Mohamed Sedky ◽  
Asmaa Hamoda ◽  
Tarek Raafat ◽  
Ayda Youssef ◽  
...  
Keyword(s):  
B Cell ◽  
Fdg Pet ◽  
Hodgkin’S Lymphoma ◽  
Pet Scan ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Fdg Pet Scan

scholarly journals Serum YKL-40 Levels in Patients with Gastric Cancer

2011 ◽  
Vol 3 ◽  
pp. BIC.S7154 ◽  
Author(s):  
Veyis Itik ◽  
Ozgur Kemik ◽  
Ahu Kemik ◽  
A. Cumhur Dulger ◽  
Aziz Sümer ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Serum Levels ◽  
Enzyme Linked Immunosorbent Assay ◽  
Colorectal Cancers ◽  
Healthy Population ◽  
Serum Samples ◽  
Future Studies ◽  
Male Patients

Aims and background YKL-40 is secreted by several types of tumors. Increased serum YKL-40 levels have been reported in prostate, glioblastoma, breast and colorectal cancers. Determination of YKL-40 levels may serve as a valuable biomarker for the diagnosis and treatment of gastric cancer. The purpose of this study was to determine the serum YKL-40 levels expressed in gastric carcinomas. Methods Between 2009 and 2011, we retrospectively reviewed 100 patients with gastric cancer and compared their serum samples to 75 healthy volunteers. YKL-40 levels were determined by an enzyme-linked immunosorbent assay (ELISA). Results We found significantly higher serum levels of YKL-40 in patients with gastric cancer compared to the healthy population ( P < 0.0001). We also found significant differences in serum YKL-40 levels between female and male patients with gastric cancer ( P < 0.01). Conclusions YKL-40 is over-expressed in gastric cancer, suggesting a more aggressive phenotype. YKL-40 may be a useful serum biomarker for gastric cancer identification, and future studies should focus on the role of YKL-40 in the tumorigenesis of gastric cancer and responsiveness toward treatment.

scholarly journals Sarcoidosis vs. Colon Cancer Metastasis: Diagnostic Dilemma and the Role of PET Scan in Monitoring Disease Activity

2021 ◽  
Vol 2021 ◽  
pp. 1-4
Author(s):  
Raai Mahmood ◽  
Kadhim Al Banaa ◽  
Israa Ibrahim ◽  
Ahmed Hashim ◽  
Luis Torregrosa
Keyword(s):  
Colon Cancer ◽  
Disease Activity ◽  
Cancer Metastasis ◽  
Pet Scan ◽  
Inflammatory Disorder ◽  
Diagnostic Dilemma ◽  
Diagnosis Of Cancer ◽  
Noncaseating Granulomas

Sarcoidosis is a systemic inflammatory disorder characterized by “noncaseating granulomas.” It primarily affects the lungs, but multiple other organs can be involved. Sarcoidosis has been increasingly reported in association with cancer. It can precede, follow or occur at the same time as the diagnosis of cancer. We report a case of sarcoidosis that was diagnosed concomitantly with colon cancer, highlighting the diagnostic dilemma of sarcoidosis vs. cancer metastasis, the relationship between the two, and the value of PET scan in follow-up and monitoring of disease activity.

Kallikrein-related peptidases and associated microRNAs as promising prognostic biomarkers in gastrointestinal malignancies

2018 ◽  
Vol 399 (8) ◽  
pp. 821-836 ◽  
Author(s):  
Panagiotis G. Adamopoulos ◽  
Panagiotis Tsiakanikas ◽  
Andreas Scorilas
Keyword(s):  
Wide Spectrum ◽  
Prognostic Significance ◽  
Prognostic Biomarkers ◽  
Colorectal Cancers ◽  
Gi Tract ◽  
Aberrant Expression ◽  
Gastrointestinal Malignancies ◽  
Expression Levels ◽  
Related Mortality

AbstractGastrointestinal (GI) malignancies represent a wide spectrum of diseases of the GI tract and its accessory digestive organs, including esophageal (EC), gastric (GC), hepatocellular, pancreatic (PC) and colorectal cancers (CRC). Malignancies of the GI system are responsible for nearly 30% of cancer-related morbidity and approximately 40% of cancer-related mortality, worldwide. For this reason, the discovery of novel prognostic biomarkers that can efficiently provide a better prognosis, risk assessment and prediction of treatment response is an imperative need. Human kallikrein-related peptidases (KLKs) are a subgroup of trypsin and chymotrypsin-like serine peptidases that have emerged as promising prognosticators for many human types of cancer, being aberrantly expressed in cancerous tissues. The aberrant expression ofKLKsin human malignancies is often regulated byKLK/microRNAs (miRNAs) interactions, as many miRNAs have been found to targetKLKsand therefore alter their expression levels. The biomarker utility ofKLKshas been elucidated not only in endocrine-related human malignancies, including those of the prostate and breast, but also in GI malignancies. The main purpose of this review is to summarize the existing information regarding the prognostic significance of KLKs in major types of GI malignancies and highlight the regulatory role of miRNAs on the expression levels ofKLKsin these types of cancer.

Giant cell arteritis mimicking fever of unknown origin: potential diagnostic role of PET scan

2006 ◽  
Vol 95 (02) ◽  
pp. 390-392 ◽  
Author(s):  
Olivier Chavaillaz ◽  
Salah Gueddi ◽  
Sophia Taylor ◽  
Hans Stalder ◽  
Marc Righini
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Fever Of Unknown Origin ◽  
Unknown Origin ◽  
Pet Scan ◽  
Diagnostic Role
Sign in / Sign up

Export Citation Format

Share Document